It has been documented that inactivation of the GSTP1 gene was often observed in human neoplasia (prostate, breast, and liver cancer, as well as leukemia) and researchers highlight GSTP1 epigenetic modifications as biomarkers for early diagnosis for cancers and potential targets of preventive or therapeutic treatments [26,27]. This evidence concerns the gene GSTP1 and liver cancer.